Verrica Pharmaceuticals Inc. Common Stock (VRCA)
Stock · NASDAQ · Health Care
$3.6as of 10/16/2026
Price chart
Active signals
VRCA Signal Track Record
How signals performed across all stocks →What VRCA's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 41 | -5.9% | 32% | September 8, 2026 |
| Bollinger Band BreakdownActive now | 23 | -2.4% | 39% | August 7, 2026 |
| Bollinger Band Breakout | 18 | +2.7% | 50% | August 28, 2026 |
| 200-Day Moving Average TouchActive now | 12 | +3.0% | 58% | July 1, 2026 |
| Any 20-session window (baseline) | -5.7% | 39% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About VRCA
Verrica Pharmaceuticals Inc., a dermatology therapeutics company, engages in the development and commercialization of medications for the treatment of dermatologic diseases in the United States. The company offers YCANTH (VP-102) a drug-device combination that contains a GMP-controlled formulation of cantharidin for the treatment of molluscum in adult and pediatric patients, as well as for the treatment of common war…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 76
- Website
- verrica.com/
Fundamentals
- 1-day range
- $3.48$3.95
- Market cap
- $92.08M
- P/E (trailing)
- —
- P/E (forward)
- -2.43
- EPS (trailing)
- $-1.67
- Dividend yield
- —
- Beta
- 1.65
- Avg. volume
- 66.0K
How Verrica Pharmaceuticals Inc. Common Stock Makes Money
Where the revenue actually goes — FY2025 annual results
Source: 10-K filed Mar 11, 2026 · via SEC EDGAR / Finnhub
Forecasts
6 analyst ratings
Verrica Pharmaceuticals Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- VRCAVerrica Pharmaceuticals Inc. Common Stock$3.6▼ 4.89%Market cap $92.08MP/E —$3.28$9.82
- FBIOFortress Biotech Inc. Common Stock$1.87▼ 2.09%Market cap $92.02MP/E 0.58$1.88$4.53
- NTHINeOnc Technologies Holdings Inc. Common Stock$2.7▼ 1.82%Market cap $90.77MP/E —$2.5$12
- BMEABiomea Fusion Inc. Common Stock$0.869▲ 3.95%Market cap $90.37MP/E —$0.800501$2.24
- HRTXHeron Therapeutics Inc. Common Stock$0.36▼ 5.26%Market cap $94.45MP/E —$0.261$1.58
- ONCYOncolytics Biotech Inc. Common Stock$0.5▼ 9.09%Market cap $95.55MP/E —$1.48$4.49
- ALDXAldeyra Therapeutics Inc. Common Stock$0.7▼ 5.02%Market cap $95.91MP/E —$0.8619$5.93
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| VRCA Verrica Pharmaceuticals Inc. Common Stock | $92.08M | — | $3.6 | ▼ 4.89% | $3.28$9.82 |
| FBIO Fortress Biotech Inc. Common Stock | $92.02M | 0.58 | $1.87 | ▼ 2.09% | $1.88$4.53 |
| NTHI NeOnc Technologies Holdings Inc. Common Stock | $90.77M | — | $2.7 | ▼ 1.82% | $2.5$12 |
| BMEA Biomea Fusion Inc. Common Stock | $90.37M | — | $0.869 | ▲ 3.95% | $0.800501$2.24 |
| HRTX Heron Therapeutics Inc. Common Stock | $94.45M | — | $0.36 | ▼ 5.26% | $0.261$1.58 |
| ONCY Oncolytics Biotech Inc. Common Stock | $95.55M | — | $0.5 | ▼ 9.09% | $1.48$4.49 |
| ALDX Aldeyra Therapeutics Inc. Common Stock | $95.91M | — | $0.7 | ▼ 5.02% | $0.8619$5.93 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
Insider Activity
Insider Actions →- Noah L. Rosenberg · August 18, 2026 · Buy2.0K @ $4.92
- John J. Kirby · August 18, 2026 · Buy5.0K @ $4.93
- David Zawitz · August 17, 2026 · Buy6.0K @ $4.98
- Jayson Rieger · August 17, 2026 · Buy5.0K @ $4.91
- Noah L. Rosenberg · August 17, 2026 · Buy4.2K @ $4.91
- Jayson Rieger · August 14, 2026 · Buy20.0K @ $5.06
- David Zawitz · June 5, 2026 · Grant171.3K
- Jayson Rieger · June 5, 2026 · Grant512.3K
- Eichenfield Lawrence · June 5, 2026 · Grant16.0K
- Nguyen Diem · June 5, 2026 · Grant16.0K
- Corcoran Gavin · June 5, 2026 · Grant16.0K
- Noah L. Rosenberg · June 5, 2026 · Grant233.8K
- PRYGOCKI MARK A SR · June 5, 2026 · Grant16.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 4.71M
- Total value held
- $24.92M
- Institutional holders
- 36
- Unknown923.9K
- Unknown707.3K
- Unknown685.1K
- Unknown518.2K
- Unknown471.6K
- Unknown280.7K
- Unknown188.8K
- Unknown153.7K
- Unknown140.5K
- Unknown138.9K
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 30, 2026
Verrica to present new YCANTH data at dermatology conferences
Verrica Pharmaceuticals announced it will present new data analysis for its drug YCANTH at two upcoming dermatology conferences. This event allows the company to share recent findings with medical professionals, which is a standard step in communicating clinical progress for its products. The stock currently trades within a wide 52-week range, reflecting the uncertainty often associated with clinical data releases.
Verrica to present new YCANTH data at dermatology conferences. Verrica Pharmaceuticals announced it will present new data analysis for its drug YCANTH at two upcoming dermatology conferences. This event allows the company to share recent findings with medical professionals, which is a standard step in communicating clinical progress for its products. The stock currently trades within a wide 52-week range, reflecting the uncertainty often associated with clinical data releases.